Stockscreener 앱 받기
4.72
7.45%
-0.38
시간 외 거래:
4.72
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
BofA Cuts Price Target on Bausch Health to $5 From $7 - marketscreener.com
TSX falls as Trump's Fed criticism shakes markets - marketscreener.com
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? - Nasdaq
Analysts Expect Bausch Health Companies Inc. (NYSE:BHC) To Breakeven Soon - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Is Bausch Health Companies (BHC) the Ridiculously Cheap Stock to Invest in? - Yahoo Finance
11 Ridiculously Cheap Stocks to Invest in - Insider Monkey
Bausch Health Provides Update on Solta Medical - marketscreener.com
U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case - TipRanks
Bausch Health shares jump on favorable court ruling By Investing.com - Investing.com South Africa
Bausch Health shares jump on favorable court ruling - Investing.com
Bausch says court grants summary judgment in favor of FDA, Salix, and Teva - TipRanks
Major Legal Win: How Bausch Health's Court Victory Protects Billion-Dollar XIFAXAN Franchise Until 2028 - Stock Titan
Fitch raises Bausch Health rating to CCC+ amid refinancing By Investing.com - Investing.com Canada
Fitch raises Bausch Health rating to CCC+ amid refinancing - Investing.com
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com
Topical Drug Delivery Market Set to Witness Significant Growth - openPR.com
Verteporfin Market Generated Opportunities, Future Scope - openPR.com
Bausch Health Companies IncAdopts Shareholder Rights PlanSEC Filing - marketscreener.com
Scar Treatment Market Set to Witness Significant Growth - openPR.com
Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment - TipRanks
Bausch Health Announces Adoption of Shareholder Rights Plan - The Joplin Globe
Bausch Health's New Poison Pill Defense: Key Details of Shareholder Protection Strategy - Stock Titan
The most oversold and overbought stocks on the TSX - The Globe and Mail
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin - marketscreener.com
Intraocular Lens Market Overall Study Report 2025-2032 | Bausch - openPR.com
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program - ACCESS Newswire
New $10K Scholarship Program Empowers Students Affected by Skin Conditions - Stock Titan
Bausch Health secures intent for acne treatment coverage By Investing.com - Investing.com South Africa
Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com
Bausch Health signs LOI with pan-Canadian Pharmaceutical Alliance for CABTREO - TipRanks
Bausch Health Canada signs Cabtreo public drug plan coverage letter of intent - TipRanks
Bausch Health secures intent for acne treatment coverage - Investing.com Australia
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris - Yahoo Finance
Bausch Health Companies Unit Entered Into A New Senior Secured Credit Agreement - MarketScreener
Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities - GlobeNewswire Inc.
Bausch Health Misses Revenue Estimates, RBC Analysts React - Finimize
Bausch Health Faces Revenue Miss And Price Target Cut - Finimize
Alex Meruelo Reports 9.99% Stake In Bausch Health Companies Inc As Of March 31SEC Filing - MarketScreener
Sector Update: Health Care Stocks Slipping in Late Afternoon Trading - MarketScreener
Bausch Health Faces Challenges Amid Price Target Downgrade - Evrim Ağacı
Bausch Health stock target cut to $8.50 by RBC Capital - Investing.com South Africa
RBC Previews Bausch Health's Q1 - MarketScreener
RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating - MarketScreener
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity - Seeking Alpha
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch Health Companies Becomes Oversold (BHC) - Nasdaq
0.47%
0.69%
자본화:
|
볼륨(24시간):